Premaitha Health

Premaitha Health is an innovative molecular diagnostics company bringing advantages in Next Generation DNA sequencing to non-invasive prenatal testing (NIPT). Premaitha’s flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening, enabling clinical laboratories to offer CE-marked NIPT in-house for the first time. The IONA® test estimates the risk of the fetus having Trisomy 21 (Down’s syndrome), Trisomy 18 (Edwards’ syndrome) and Trisomy 13 (Patau’s syndrome). The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha’s clinical laboratory customers to perform the test in their laboratory, using existing clinical workflow. The IONA® test has a higher detection rate and lower false positive rate giving pregnant women, their families and their doctors’ greater confidence in the result thereby reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress. Premaitha’s strategy aims to accelerate the broad dissemination of advanced NIPT tests to benefit more laboratories, doctors and pregnant women.
Premaitha is listed on the London Stock Exchange’s Alternative Investment Market (AIM). Its R&D, manufacturing and commercial operation is located on the Manchester Science Park, UK.

Type
Public
HQ
Manchester, GB
Founded
2013
Size (employees)
43 (est)
Premaitha Health was founded in 2013 and is headquartered in Manchester, GB

Premaitha Health Office Locations

Premaitha Health has an office in Manchester
Manchester, GB (HQ)
Rutherford House 40 Pencroft Way

Premaitha Health Data and Metrics

Premaitha Health Financial Metrics

Premaitha Health's revenue was reported to be £2.5 m in FY, 2016 which is a 1754% increase from the previous period.
Numbers are in £, GBP

Revenue (FY, 2016)

2.5 m

Revenue growth (FY, 2015 - FY, 2016), %

1754%

Gross profit (FY, 2016)

701 k

Gross profit margin (FY, 2016), %

29%

Net income (FY, 2016)

(12.1 m)

Market capitalization (26-May-2017)

24.5 m

Closing share price (26-May-2017)

0.1

Cash (31-Mar-2016)

5.3 m
Premaitha Health's current market capitalization is £24.5 m.
Numbers are in £, GBPFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

257.7 k102.5 k132.3 k2.5 m

Revenue growth, %

(60%)29%1754%

Cost of goods sold

555.2 k1.8 m

Gross profit

(297.5 k)701 k

Gross profit Margin, %

(115%)29%

Operating expense total

4.7 m12.7 m

Pre tax profit

(1.5 m)(7.4 m)(12.1 m)

Net Income

(1.6 m)(7.4 m)(12.1 m)
Numbers are in £, GBPFY, 2014FY, 2015FY, 2016

Cash

49.9 k2.7 m5.3 m

Accounts Receivable

60 k964.2 k

Current Assets

500.6 k4.3 m8.6 m

PP&E

436.4 k1.3 m1.9 m

Total Assets

937 k5.6 m10.5 m

Accounts Payable

283.1 k937.5 k1.1 m

Current Liabilities

850.6 k1.6 m7.5 m

Retained Earnings

(1.6 m)(7.4 m)(12.1 m)

Total Equity

(1.6 m)3.9 m1.5 m

Financial Leverage

-0.6 x1.4 x7.1 x
Numbers are in £, GBPFY, 2014FY, 2015FY, 2016

Cash From Operating Activities

(1.5 m)(5 m)(7 m)

Cash From Financing Activities

2 m7.5 m10.8 m

Income Taxes Paid

(39.5 k)39.5 k
Numbers are in £, GBPY, 2016

Revenue/Employee

98.1 k

Financial Leverage

7.1 x

Premaitha Health Market Value History

Premaitha Health Online and Social Media Presence

Premaitha Health News and Updates

Premaitha Health Company Life and Culture

You may also be interested in